CRSP vs BEAM
CRSP and BEAM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | BEAMBeam Therapeutics Inc. |
|---|---|---|
| Market cap | $4.68B | $2.73B |
| P/B | — | 2.34 |
| P/S | 1318.7x | 18.9x |
| Revenue | — | $164.01M(TTM) |
| Revenue growth (YoY) | -90.6% | 120.0% |
| Net income | — | -$65.98M(TTM) |
| Earnings growth (YoY) | -58.8% | 78.8% |
| EPS, diluted | — | $-0.49(TTM) |
| EBIT margin | -18933.6% | -274.6% |
| ROE | -32.1% | -6.9% |
| ROIC | -33.6% | -39.3% |
| 1y total return | -16.7% | +27.2% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: CRSP vs BEAM
| 지표 | CRSP | BEAM |
|---|---|---|
| 최종 가치 | $8.9K | $14.1K |
| 총수익률 | -10.8% | +41.3% |
| CAGR | -1.8% | +5.5% |
| 변동성 | 61.8% | 80.1% |
| 샤프 | 0.22 | 0.41 |
| 소르티노 | 0.33 | 0.64 |
| 최대 낙폭 | -85.1% | -89.1% |
공통 거래일 1628일 기준, 2020-02-06 → 2026-07-30 · 무위험수익률 3.83% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)